Clinical Trial AI Playbook

Clinical trials are expensive, slow, and failure-prone. A Phase III failure costs $100M+. AI does not eliminate that risk, but it can meaningfully reduce it at multiple points in the trial lifecycle - if deployed in the right places, with the right expectations.

This playbook covers seven application areas where AI has demonstrated real clinical value. For each: what it actually does, when to deploy it, which vendors are worth knowing, what typically goes wrong, and a concrete example.

1. Protocol Optimization and Design Simulation

What it does

AI models simulate protocol designs before a trial begins - testing endpoint sensitivity, estimating statistical power across design variants, and flagging protocol elements that historically drive dropout or site burden. This replaces weeks of manual sensitivity analysis with hours of computational exploration.

When to use it

Early feasibility stage, before protocol lock. Most valuable for complex adaptive designs, rare disease trials where each patient matters, or indications with heterogeneous patient populations.

Key tools and vendors

  • Unlearn.ai - Digital twins for control arm augmentation. Generates synthetic control subjects from historical data, reducing required placebo arm size.
  • Trials.ai (now part of Medidata) - Protocol complexity scoring and amendment risk prediction.
  • Saama Technologies - Study design and feasibility analytics.
  • In-house teams often use Python (statsmodels, scipy) with historical internal trial data for endpoint simulation.

Common pitfalls

  • Simulations are only as good as the historical data they train on. If your historical trials had systematic biases (e.g., exclusion of elderly patients), the simulation inherits them.
  • Protocol optimization AI tends to optimize for enrollment speed, which can conflict with scientific rigor. Define what you are actually optimizing for before you start.

Concrete example

A mid-size BioPharma used historical Phase II data from 8 previous oncology trials to simulate 200 endpoint variants for a new CAR-T study. The simulation identified that switching the primary endpoint from overall survival at 12 months to event-free survival at 18 months would reduce required sample size by 22% while maintaining 90% power. The change was implemented before IND submission.

2. Patient Matching and Recruitment

What it does

NLP and ML models parse EHR data - clinical notes, lab values, imaging reports, diagnosis codes - to identify patients who match eligibility criteria. More sophisticated systems also model likelihood-to-enroll based on patient history, logistics, and prior trial participation.

When to use it

Site selection and pre-screening stages. Most impactful for rare diseases, narrow inclusion criteria, or trials that rely on complex biomarker eligibility (e.g., specific genomic alterations).

Key tools and vendors

  • Medidata Rave with CTMS integrations - standard infrastructure at most large sites.
  • TriNetX - Real-world data network for feasibility and pre-screening across participating health systems.
  • Antidote (acquired by Fierce Biotech) - Patient-facing matching for direct recruitment.
  • ProofPilot - Decentralized trial recruitment with AI-assisted matching.

Common pitfalls

  • EHR data quality is highly variable. Structured fields (ICD codes, lab values) are reliable. Free-text clinical notes require NLP and introduce error rates that must be validated at each site.
  • Diversity optimization is genuinely hard. AI models trained on historical trial populations will reproduce historical underrepresentation unless you explicitly constrain the objective function to target demographic balance.
  • HIPAA compliance: patient data used for pre-screening must be handled under a IRB-approved protocol or covered by the site's research authorization. Do not let a vendor assume this is handled.

Concrete example

A large academic medical center ran NLP across 3 years of oncology notes to identify KRAS G12C mutation patients who had not yet enrolled in any trial. The model flagged 847 potential candidates. Manual review confirmed 312 were eligible. 89 enrolled - compared to 14 in the prior year using manual chart review. Enrollment cost dropped 60%.

3. Site Selection and Feasibility Scoring

What it does

ML models score clinical sites on predicted enrollment performance, protocol compliance history, investigator experience, patient pool characteristics, and infrastructure readiness. Replaces gut-feel site selection with data-driven ranking.

When to use it

Before site activation, especially for global trials where you cannot visit every candidate site. Also useful mid-trial for deciding where to add rescue sites.

Key tools and vendors

  • Veeva Vault CTMS with site performance analytics.
  • IQVIA Orchestrated Customer Engagement - Site intelligence and feasibility tools.
  • Advera Health Analytics - Site performance benchmarking using FDA adverse event data.

Common pitfalls

  • Historical site performance data is often siloed per sponsor. A site that performed poorly for Sponsor A may have fixed its issues and perform well for you. Cross-sponsor data sharing (where it exists) helps, but verify recency.
  • Geographic analysis for patient access must account for decentralized trial capabilities - telehealth, home nursing, remote monitoring. Sites that score low on traditional metrics may score high on hybrid trial readiness.

Concrete example

A CRO building a Phase II neurology trial used a site scoring model trained on 5 years of internal enrollment data. The model ranked 60 candidate sites. The top 20 by model score enrolled 73% of all patients. The bottom 20 contributed 4%. In the prior year's analog trial selected by manual review, performance was distributed much more evenly - and 3 sites had to be dropped mid-trial for persistent underenrollment.

4. Risk-Based Monitoring

What it does

RBM uses ML to score sites and patients on risk signals - data entry anomalies, protocol deviations, missing data patterns, adverse event rates - and directs monitoring resources to the highest-risk areas. Replaces 100% source data verification (SDV) with targeted oversight.

When to use it

Virtually all trials of Phase II and above. FDA and EMA both explicitly support RBM in guidance. Sponsors running traditional 100% SDV are spending 30-40% more on monitoring than necessary.

Key tools and vendors

  • Medidata Rave RBQM - Market leader, integrates natively with Rave EDC.
  • Oracle Siebel CTMS with Risk Console - Common in large pharma.
  • CluePoints - Statistical detection of data anomalies across sites, particularly good at identifying systemic fraud or data fabrication patterns.
  • Veeva Vault RIM - Audit trail and compliance monitoring.

Common pitfalls

  • RBM requires central monitoring staff who can actually interpret risk signals. Deploying the software without training the team to act on outputs produces expensive dashboards, not better trials.
  • Risk thresholds need calibration per indication. A deviation rate that is alarming in oncology may be normal in a complex neurology protocol. Do not use out-of-the-box thresholds without validation.

Concrete example

A Phase III cardiovascular trial switched from 100% SDV to RBM halfway through. The model flagged one site for unusual AE under-reporting - a pattern consistent with selective reporting. An on-site audit confirmed the issue and the site was suspended. The estimated cost saving from reduced monitoring across the other 40 sites was $2.1M over the remaining trial period.

5. Adaptive Trial Design with Bayesian ML

What it does

Bayesian ML models update in real-time as trial data arrives, enabling pre-specified interim decisions: dose adjustment, arm dropping, sample size re-estimation, or early stopping for efficacy or futility. The model continuously recalculates posterior probabilities rather than waiting for pre-specified looks.

When to use it

Dose-finding studies, platform trials, and any design where you want pre-specified flexibility to respond to emerging data. Requires FDA pre-alignment on the adaptive design - do not use without a pre-Sub meeting.

Key tools and vendors

  • Berry Consultants - The gold standard for Bayesian adaptive trial design. Have run 500+ adaptive trials.
  • Cytel EAST Bayes - Software for designing and simulating Bayesian adaptive trials.
  • RCT Logic (now Landmark Science) - Platform trial infrastructure.

Common pitfalls

  • Adaptive designs require extensive pre-trial simulation. The simulation assumptions (dropout rates, effect size distributions) must be defensible to FDA. Underinvesting in simulation means the adaptation rules may not work as intended.
  • Operational complexity is real. Adaptive decisions require a DMC and an independent statistical team with a firewall from the sponsor. Build this into your budget and timeline.

6. Real-World Evidence Generation

What it does

NLP, computer vision, and ML extract structured endpoints from real-world data sources - EHR, claims, registries, wearables - to augment or replace traditional endpoints. AI is the enabling layer that makes RWE at scale feasible.

When to use it

Post-approval label expansion, pragmatic trials, and health economics studies. FDA's 2021 Real-World Evidence Framework and subsequent guidance documents define acceptable use cases for RWE in regulatory submissions.

Common pitfalls

  • Confounding is the central challenge in RWE. AI can match patients on observed characteristics; it cannot control for unmeasured confounders. Be rigorous about causal inference methodology, not just predictive performance.
  • Claims data lags clinical reality by 30-90 days. For studies with time-sensitive endpoints, claims-based RWE will systematically undercount events in recent periods.

7. Safety Signal Detection

What it does

ML models monitor adverse event data for emerging safety signals - both within a trial and across the broader pharmacovigilance data (FAERS, VAERS, EudraVigilance). NLP extracts events from narrative AE reports that do not get coded into structured MedDRA terms.

Key tools and vendors

  • Oracle Argus Safety - Standard pharmacovigilance platform with ML signal detection add-ons.
  • Veeva Vault Safety - Competitor to Argus, increasingly common in mid-size pharma.
  • Saama AI Safety - Purpose-built AI for safety signal detection and narrative coding.

Common pitfalls

  • High false positive rates are the norm in signal detection. A signal is a hypothesis, not a finding. Build a triage process so your safety team is not drowning in false alarms.
  • NLP-coded AEs from narrative reports have coding errors. Validate the model on a representative sample before using it for regulatory submissions.

AI in clinical trials is not a magic layer you add to a broken process. It amplifies what is already there. A well-run trial with good data discipline will see real benefit. A trial with poor protocol design, inconsistent site management, and messy EDC data will just generate AI-flavored noise faster. Get the fundamentals right first.

You might also like

Further Reading